SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-12-31 was 6.66K shares, a 85.21% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-09-30 was 4.74K shares, a 93.80% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-06-30 was 26.02K shares, a 52.82% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2014-03-31 was 48.58K shares, a 24.56% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 225.23K shares, a 73.51% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 850.12K shares, a 60.73% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 528.91K shares, a 66.19% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 318.26K shares, a 12.21% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 225.23K shares 10-K · filed 2026-03-02 | |
| 2024-12-31 | 850.12K shares 10-K · filed 2025-02-28 | |
| 2023-12-31 | 528.91K shares 10-K · filed 2024-02-28 | |
| 2022-12-31 | 318.26K shares 10-K · filed 2023-02-28 | |
| 2021-12-31 | 283.62K shares 10-K · filed 2022-03-01 | |
| 2020-12-31 | 1.45M shares 10-K · filed 2021-03-01 | |
| 2019-12-31 | 1.06M shares 10-K · filed 2021-03-01 | |
| 2018-12-31 | 2.12M shares 10-K · filed 2021-03-01 | |
| 2017-12-31 | 792.85K shares 10-K · filed 2020-02-26 | |
| 2016-12-31 | 1.06M shares 10-K · filed 2019-02-28 | |
| 2015-12-31 | 816.70K shares 10-K · filed 2018-03-01 | |
| 2014-12-31 | 6.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | 86.01K shares 10-K · filed 2017-02-28 |
| 2014-09-30 | 4.74K shares 10-Q · filed 2014-11-06 | 124.39K shares derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | 26.02K shares 10-Q · filed 2014-08-07 | 196.11K shares derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | 48.58K shares 10-Q · filed 2014-05-08 | 225.25K shares derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | 45.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | 241.06K shares 10-K · filed 2016-02-25 |
| 2013-09-30 | 76.47K shares 10-Q · filed 2014-11-06 | 400.02K shares derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | 55.16K shares 10-Q · filed 2014-08-07 | 490.79K shares derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | 64.39K shares 10-Q · filed 2014-05-08 | |
| 2012-12-31 | 204.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | 371.35K shares 10-K · filed 2015-02-26 |
| 2012-09-30 | 167.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | |
| 2011-12-31 | 25.29K shares 10-K · filed 2014-03-03 | |
| 2010-12-31 | 283.61K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |